(Q35879902)

10 August 2017

1 reference

title

Current and new strategies in immunotherapy for superficial bladder cancer (English)

1 reference

10 August 2017

1 reference

Frank G E Perabo

1

1 reference

PubMed ID

15351555

10 August 2017

Stefan C Müller

series ordinal

2

1 reference

PubMed ID

15351555

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

10 August 2017

1 reference

10 August 2017

64

1 reference

10 August 2017

409-421

1 reference

10 August 2017

3

1 reference

10 August 2017

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Prognostic parameters in superficial bladder cancer: an analysis of 315 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Superficial bladder cancer: progression and recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer--results of a controlled prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Prospective phase II trial of alternating intravesical Bacillus Calmette-Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Intravesical interferon treatment of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Treatment of superficial bladder tumors with intravesical recombinant interferon alpha-2a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Intravesical therapy of superficial bladder transitional cell carcinoma with tumor necrosis factor-alpha: preliminary report of a phase I-II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Recombinant tumor necrosis factor for superficial bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy--a phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.04.026

10.1016/J.UROLOGY.2004.04.026

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15351555